A Study of JNJ-87890387 for Advanced Solid Tumors
- First Posted Date
- 2023-12-21
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 158
- Registration Number
- NCT06178614
- Locations
- 🇪🇸
Hosp Univ Vall D Hebron, Barcelona, Spain
🇺🇸Start Midwest, Grand Rapids, Michigan, United States
🇫🇷Centre Leon Berard, Lyon, France
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
- Conditions
- Interventions
- First Posted Date
- 2023-11-29
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 100
- Registration Number
- NCT06150157
- Locations
- 🇩🇪
Universitaetsklinikum Regensburg, Regensburg, Germany
🇺🇸City of Hope, Duarte, California, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 774
- Registration Number
- NCT06143878
- Locations
- 🇧🇷
Fundacao do ABC Centro Universitario FMABC, Santo Andre, Brazil
🇵🇱WroMedica I.Bielicka, A.Strzalkowska s.c., Wrocław, Poland
🇺🇸Medical Dermatology Specialists, Phoenix, Arizona, United States
A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 70
- Registration Number
- NCT06139406
- Locations
- 🇦🇺
Austin Hospital, Heidelberg, Australia
🇦🇺The Alfred Hospital, Melbourne, Australia
🇦🇺Linear Clinical Research Ltd, Nedlands, Australia
A Study of 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 959
- Registration Number
- NCT06134804
- Locations
- 🇨🇦
Aggarwal and associates Ltd, Brampton, Ontario, Canada
🇺🇸Atlanta Center for Medical Research, Atlanta, Georgia, United States
🇺🇸Suncoast Research Associates, LLC, Miami, Florida, United States
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 200
- Registration Number
- NCT06120140
- Locations
- 🇺🇸
USC Norris Oncology Hematology Newport Beach, Newport Beach, California, United States
🇺🇸Kaiser Permanente Oakland Medical Center, Oakland, California, United States
🇺🇸Kaiser Permanente Roseville Medical Center, Roseville, California, United States
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 311
- Registration Number
- NCT06095102
- Locations
- 🇺🇸
Arlington Dermatology, Rolling Meadows, Illinois, United States
🇺🇸Dundee Dermatology, West Dundee, Illinois, United States
🇺🇸Dawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana, United States
A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 130
- Registration Number
- NCT06095089
- Locations
- 🇺🇸
South Texas Accelerated Research Therapeutics, LLC (START), San Antonio, Texas, United States
🇫🇷Centre Leon Berard, Lyon, France
🇺🇸University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 684
- Registration Number
- NCT06095115
- Locations
- 🇺🇸
Oregon Dermatology and Research Center, Portland, Oregon, United States
🇺🇸The Pennsylvania Centre for Dermatology, LLC, Exton, Pennsylvania, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 252
- Registration Number
- NCT06049017
- Locations
- 🇺🇸
Hoag Memorial Hospital, Newport Beach, California, United States
🇺🇸Clinnova Research, Orange, California, United States
🇺🇸Medical Associates Research Group, Inc., San Diego, California, United States